Propensity score matching, competing risk analysis, and a competing risk nomogram: Some guidance for urologists may be in place

European Urology

Volumn 60, Issue 5, 2011, Pages 931-933

  Roobol, Monique J ^a   Heijnsdijk, Eveline A M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CAUSE OF DEATH; COMPETING RISK ANALYSIS; COMPETING RISK NOMOGRAM; EDITORIAL; GLEASON SCORE; HUMAN; NOMOGRAM; PRIORITY JOURNAL; PROPENSITY SCORE; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 80053334361     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.07.039     Document Type: Editorial

References (13)

1. W.J. Catalona, D.S. Smith, and T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
2. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
3. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878 (Pubitemid 36833878)
4. S.K. Steginga, E. Turner, and J. Donovan The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research World J Urol 26 2008 469 474
5. F. Schröder, and M.W. Kattan The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review Eur Urol 54 2008 274 290
6. F. Abdollah, M. Sun, and J. Schmitges Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort Eur Urol 60 2011 920 930
7. PR06 Collaborators Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial BJU Int 94 2004 1400 1401
8. J.A. Lane, F.C. Hamdy, R.M. Martin, E.L. Turner, D.E. Neal, and J.L. Donovan Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies Eur J Cancer 46 2010 3095 3101
9. Z. Luo, J.C. Gardine, and C.J. Bradley Applying propensity score methods in medical research: pitfalls an prospects Med Care Res Rev 67 2010 528 553
10. A.J. Vickers, A.M. Cronin, and T. Björk Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
11. A.J. Stephenson, M.W. Kattan, and J.A. Eastham Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era J Clin Oncol 27 2009 4300 4305
12. A.J. Vickers, C.J. Savage, and F.J. Bianco Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience Int J Cancer 128 2011 1697 1702
13. R.C.N. van den Bergh, S. Roemeling, M.J. Roobol, W. Roobol, F.H. Schröder, and C.H. Bangma Prospective validation of active surveillance in prostate cancer: the PRIAS study Eur Urol 52 2007 1560 1563 (Pubitemid 350052404)